Literature DB >> 7889618

p53 gene mutations in pituitary adenomas: rare events.

A Levy1, L Hall, W A Yeudall, S L Lightman.   

Abstract

OBJECTIVE: Occult pituitary adenomas are said to occur in up to 20% of random autopsy examinations, yet the only oncogene known to be associated with pituitary adenomas, gsp, is found in only 40% of somatotrophinomas, a subtype that accounts for a minority of pituitary tumours. Mutations of the p53 tumour suppressor gene are thought to be involved in the pathogenesis of as many as 50% of all human cancers, including tumours of the central nervous system. The objective of this study was to determine whether p53 gene mutations are associated with pituitary adenomas. DESIGN AND PATIENTS: Fragments of pituitary adenoma tissue from 29 patients undergoing routine hypophysectomy for pituitary tumour were coated in cryostat embedding medium and frozen at -80 degrees C within 24 hours of resection. They consisted of 9 somatotroph, 4 corticotroph, 1 mammotroph and 15 endocrinologically inactive adenomas, all of the non-invasive clinical phenotype. Sequential frozen sections were subjected to in situ hybridization analysis for anterior pituitary hormone transcripts and examined histologically to ensure that the frozen sections used to generate DNA templates for polymerase chain reaction amplification were not contaminated with non-tumour tissue. MEASUREMENTS: p53 exons 7 and 8, within which 98% of substitution mutations are thought to occur, and exons 4-6 in tumours immunopositive for p53, were amplified by polymerase chain reaction and ligated into the vector pCR2. DNA from small-scale plasmid preparations of pCR2 containing cloned p53 exons from human pituitary adenomas was sequenced using an automated fluorescence-based system (DuPont Genesis 2000) and compared with wild-type sequence. Apparent mutations were confirmed or refuted by sequencing a further 2-4 clones isolated from the same template.
RESULTS: Although immunocytochemical staining patterns for wild-type p53 varied markedly between different tumours, no mutations were identified in any of the exonic sequences examined.
CONCLUSIONS: p53 mutations, at least within the high mutation domains of p53, occur infrequently in human pituitary adenomas. Increased steady-state levels of p53 protein identified immunocytochemically may be a consequence of binding to other cellular proteins in these tumours.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7889618     DOI: 10.1111/j.1365-2265.1994.tb02797.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  36 in total

1.  Mid-term prognosis of non-functioning pituitary adenomas with high proliferative potential: really an aggressive variant?

Authors:  Yoshikazu Ogawa; Hidefumi Jokura; Kuniyasu Niizuma; Teiji Tominaga
Journal:  J Neurooncol       Date:  2018-01-09       Impact factor: 4.130

2.  Somatostatin-producing atypical null cell adenoma manifesting as severe hypopituitarism and rapid deterioration--case report.

Authors:  Yoshikazu Ogawa; Mika Watanabe; Teiji Tominaga
Journal:  Endocr Pathol       Date:  2010-06       Impact factor: 3.943

3.  Identification of growth arrest and DNA-damage-inducible gene beta (GADD45beta) as a novel tumor suppressor in pituitary gonadotrope tumors.

Authors:  Katherine A Michaelis; Aaron J Knox; Mei Xu; Katja Kiseljak-Vassiliades; Michael G Edwards; Mark Geraci; B K Kleinschmidt-DeMasters; Kevin O Lillehei; Margaret E Wierman
Journal:  Endocrinology       Date:  2011-08-02       Impact factor: 4.736

4.  Role of a p53 polymorphism in the development of nonfunctional pituitary adenomas.

Authors:  Garima Yagnik; Arman Jahangiri; Rebecca Chen; Jeffrey R Wagner; Manish K Aghi
Journal:  Mol Cell Endocrinol       Date:  2017-02-16       Impact factor: 4.102

Review 5.  Pathogenesis of prolactinomas.

Authors:  Anna Spada; Giovanna Mantovani; Andrea Lania
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

Review 6.  Pathogenesis of non-functioning pituitary adenomas.

Authors:  Maria Chiara Zatelli
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

Review 7.  Growth factors in the pathogenesis of prolactin-secreting tumors.

Authors:  C Missale; P F Spano
Journal:  J Endocrinol Invest       Date:  1998-06       Impact factor: 4.256

8.  Gene mutations in Cushing's disease.

Authors:  Qi Xiong; Wei Ge
Journal:  Biomed Rep       Date:  2016-07-29

9.  The Role of p16 and MDM2 Gene Polymorphisms in Prolactinoma: MDM2 Gene Polymorphisms May Be Associated with Tumor Shrinkage.

Authors:  Seda Turgut; Muzaffer Ilhan; Saime Turan; Ozcan Karaman; Ilhan Yaylim; Ozlem Kucukhuseyin; Ertugrul Tasan
Journal:  In Vivo       Date:  2017 May-Jun       Impact factor: 2.155

Review 10.  Mechanisms for pituitary tumorigenesis: the plastic pituitary.

Authors:  Shlomo Melmed
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.